AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05637164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine bitartrate
Description: The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
Study NCT05973292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate
Description: Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
Study NCT05306262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis session
Description: Comfort hypnosis: accompaniment of a pleasant memory.
Study NCT05306262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Description: Comfort hypnosis: accompaniment of a pleasant memory.
Study NCT05306262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catalepsy
Description: Catalepsy of the hand.
Study NCT04904744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low tailored message
Description: 2 low tailored text or phone message reminders that child is overdue for well child check visit
Study NCT04904744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No message
Description: No reminders are sent
Study NCT04904744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low tailored message plus COVID-19 vaccine message
Description: 2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
Study NCT06537765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
Study NCT06537765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US)
Description: Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
Study NCT06537765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
Study NCT06637488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleft lip repair using fisher technique
Description: Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
Study NCT06637488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleft lip repair using fisher technique
Description: Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
Study NCT04884477 — intervention group
Intervention type: BIOLOGICAL
Intervention: Convalescent Plasma
Description: Convalescent Plasma
Study NCT05272020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CPET, 6MWT, QOL assessment
Description: Preoperative and postoperative (6 months + 18 months) assessment
Study NCT05634694 — intervention group
Intervention type: OTHER
Intervention: No interventions.
Description: No interventions.
Study NCT05642065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip muscle activation home exercise program
Description: Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
Study NCT06347692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antigravity treadmill
Description: An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
Study NCT06347692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy exercise program
Description: Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
Study NCT04743401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exergaming Tablet
Description: The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program.
Study NCT05488925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: Evion, 400 mg
Study NCT05488925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Voltral SR100, 100 mg
Study NCT05488925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: Feldene, 20 mg
Study NCT05488925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramal, 50 mg
Study NCT04516941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Tablets
Description: Treatment
Study NCT04516941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: Treatment
Study NCT05751161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional gait training
Description: The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
Study NCT05751161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional gait training
Description: The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
Study NCT05113810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ01
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Study NCT05113810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19
Study NCT05832359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Panoramic rad.
Description: In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
Study NCT01168375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy plus umbilical cord serum eye drop
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
Study NCT05273372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment with the food white rice flour. 1,000 mg BID
Study NCT05273372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food - Anhydrous Enol-Oxaloacetate
Description: Active treatment with oxaloacetate. 1,000 mg BID
Study NCT01168375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
Study NCT05512845 — intervention group
Intervention type: PROCEDURE
Intervention: Double Factor technique
Description: The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery.
Study NCT06250504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE (cabotegravir) 600 mg\3 mL
Description: choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
Study NCT06250504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPIRING (Dapivirine) 25mg Vaginal Ring
Description: The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
Study NCT06250504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil and emtricitabine
Description: The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
Study NCT06250504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil and emtricitabine
Description: The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
Study NCT06250504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil, Lamuvidine and Dolutegravir
Description: The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
Study NCT05758051 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: subtrochanteric valgus osteotomy
Description: subtrochanteric valgus osteotomy
Study NCT05394181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
Study NCT00962481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimosiamose
Study NCT00962481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06367049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation-specific PCR
Description: Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly.
Study NCT05973292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non MDP containg resin cement
Description: Adhesive resin cement not containing an MDP agent
Study NCT06281600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharide
Description: 5g daily dose of HMOs.
Study NCT06281600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: 5g daily dose of maltodextrin.
Study NCT04555291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
Study NCT04555291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NACL
Description: Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
Study NCT06065943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Palpation and Fluoroscopy
Description: Vessel puncture guided palpation and fluoroscopy only
Study NCT06065943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guidance
Description: Vessel puncture guided by Ultrasound
Study NCT04890769 — intervention group
Intervention type: DEVICE
Intervention: Moisture sensor wound dressing
Description: Clinical procedure for change of wound dressing
Study NCT04856371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
Study NCT04856371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
Study NCT04856371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
Study NCT06026423 — intervention group
Intervention type: OTHER
Intervention: Clinical examination and pictures
Description: A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
Study NCT06026423 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
Study NCT04856371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
Study NCT06445010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creating Musical Playlist
Description: Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
Study NCT03749850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTLD
Description: Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol.
Study NCT03749850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU induced hyperthermia
Description: Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol.
Study NCT03749850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol.
Study NCT06004089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V NOTES Sacrocolpopexy
Description: The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
Study NCT06261385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: typology-based intervention
Description: A typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit
Study NCT04776096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate 1.5% PF
Description: Bepotastine besilate 1,5% Preservative free ophthalmic solution
Study NCT04776096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride 0.2% BAK
Description: Olopatadine hydrochloride 0.2% with BAK as preservative
Study NCT06267300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
Study NCT04724213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Testing of reliability / validity of new questionnaire
Description: Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
Study NCT04971980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC infusion (BC-U001)
Description: The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
Study NCT06398665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-Burst Stimulation
Description: Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
Study NCT05316350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device
Study NCT05316350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device
Study NCT06107374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG
Description: Two PET scans
Study NCT05966090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
Study NCT05966090 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).